MorphoSys Initiates Phase 2/3 Trial of CD19 Antibody MOR208 plus Bendamustine in Patients with Relapsed or Refractory DLBCL
06 sept. 2016 01h39 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Sept. 6, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the first patient has been dosed in the safety...
MorphoSys to Present at Upcoming Investor Conferences
29 août 2016 09h09 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Aug. 29, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
Commerzbank Sector...
MorphoSys Successfully Completes Safety Run-in of MOR208 in L-MIND Combination Study in Patients with DLBCL
03 août 2016 01h32 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, Aug. 3, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has successfully completed the safety run-in...
MorphoSys AG Reports Results for the First Six Months of 2016
01 août 2016 01h06 HE
|
MorphoSys AG
Financial Guidance for 2016 Confirmed
Conference call and webcast (in English) today at 2:00pm CEST (1:00pm BST/8:00am EDT)
MARTINSRIED / MUNICH, Germany, Aug. 1, 2016 (GLOBE NEWSWIRE)...
MorphoSys to Host Q2 2016 Conference Call on August 1, 2016
25 juil. 2016 08h07 HE
|
MorphoSys AG
MARTINSRIED and MUNICH, Germany, July 25, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first six months' 2016 results on August 1, 2016 at 7:00 am...
MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody
04 juil. 2016 01h32 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, July 4, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has received a milestone payment from...
MorphoSys Reports Publication of Clinical Case Report of a Blood Cancer (DLBCL) Patient Showing Long-Lasting Complete Remission of Currently 26 Months under MOR208 Treatment
17 juin 2016 02h16 HE
|
MorphoSys AG
MARTINSRIED / MUNICH, Germany, June 17, 2016 (GLOBE NEWSWIRE) -- Case study from clinical phase 2a trial with MOR208 in relapsed/refractory NHL published in the Journal of Medical Case...
MorphoSys Presents Updated Clinical Data for MOR202 in Multiple Myeloma and for MOR208 in Non-Hodgkin's Lymphoma at ASCO 2016
06 juin 2016 09h46 HE
|
MorphoSys AG
MARTINSRIED and MUNICH, Germany, June 6, 2016 (GLOBE NEWSWIRE) -- MOR202 Combination Therapy with Complete Remissions in Multiple Myeloma
MOR202 (8 mg/kg) plus Pom/Dex in relapsed/refractory multiple...
MorphoSys AG Reports Outcome of Annual General Meeting 2016
02 juin 2016 09h26 HE
|
MorphoSys AG
MARTINSRIED and MUNICH, Germany, June 2, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) reported the outcome of the Company's Annual General Meeting, which took place...
MorphoSys to Present at Six Upcoming Conferences
01 juin 2016 08h06 HE
|
MorphoSys AG
MARTINSRIED and MUNICH, Germany, June 1, 2016 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:
MorphoSys Investor...